Sponsors ECM2026

At BMS, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients. We apply scientific rigor to produce clinical and economic benefit through medicines that improve patients’ lives. We strive to make information about our commercialized medicines widely and readily available. We actively seek to improve access to care, advocate for policies that promote health equity, and help underserved patients access and afford the medicines they need. We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues.

Nordic Bioscience specializes in precision medicine using extracellular matrix Protein Fingerprint biomarkers. All chronic diseases are characterized by an imbalance of the extracellular matrix with elevated levels of either protein formation or degradation. Nordic Biosciences specialized extracellular matrix Protein Fingerprint technology measures the tissue imbalance seen in all chronic diseases.

Nordic Bioscience improve patient care by combining the Protein Fingerprint technology with their expertise in preclinical and clinical research. They assist the improvement of drug development by better selection of patients and reduction of trial length and size.

Nordic Bioscience’s approach is highly scientific, and they are proud to publish their results frequently in leading journals worldwide

Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and a global leader in in-vitro diagnostics. The company is dedicated to scientific excellence, discovering and developing medicines and diagnostics to improve and save lives. A pioneer in personalized healthcare, Roche aims to transform healthcare delivery by partnering with many stakeholders, combining strengths in Diagnostics and Pharma with clinical data insights.

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, pain and itch. In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry. For more information about AnaBios, visit http://www.anabios.com.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of fibroblast-based therapeutics for diabetic foot ulcers (DFUs), multiple sclerosis, degenerative disc disease (DDD), psoriasis, joint cartilage repair, thymus based immune system revitalization for human longevity, and cancer.

FibroFind is a rapidly developing Newcastle-based biomedical sciences company that has a deep understanding of the biology of fibrosis and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to prevent fibrosis and halt disease. The business focus for FibroFind is their proprietary human fibrosis bioassays that provide a pre-clinical service for pharmaceutical and biotechnology companies developing medicines that target fibrosis. This business model has proved to be highly valued by its growing client base which currently stands at 90 companies based in the USA, Asia and Europe. Despite only beginning trading 3 years ago, FibroFind has already contributed towards new medicines entering into ongoing clinical trials.

The GI2  TAU Early Development & Biomarkers (EDB) organization accelerates innovative therapies. EDB integrates Early Clinical Development, Early Phase Global Program Leads, Biomarker Leadership, and Computational Biology & Digital to drive datadriven decisionmaking across programs. With dedicated teams in inflammation and fibrosis biology, clinical execution, and translational science, EDB strengthens crossfunctional alignment, enhances scientific rigor, and ensures efficient progression of GI2’s earlyphase portfolio.

Xylyx Bio is a biotechnology company based in Brooklyn, New York, with integrated research and development laboratories and manufacturing facilities. The company specializes in the development, manufacturing, and commercialization of tissue-derived decellularized extracellular matrix (dECM) kits and assays for human disease modeling and drug testing. Leveraging its InMatrico® platform and TissueSpec® dECM product line, Xylyx Bio translates advances in extracellular matrix biology into standardized, scalable research tools. These products enable scientists to incorporate tissue-specific dECM into in-vitro models, enhancing physiological relevance and improving disease modeling fidelity. By more accurately recapitulating human tissue-specific extracellular microenvironments, Xylyx Bio is helping to bridge the gap between conventional laboratory models and human biology.

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, neuroscience and oncology – and through our Allergan Aesthetics portfolio.

As a focused biopharma company, GSK discover, develop and deliver medicines and vaccines to create value for patients and shareholders. GSK aim to positively impact the health of 2.5 billion people by the end of the decade.  GSK’s R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

Gubra is a disease-agnostic company specializing in peptide-based drug discovery and preclinical contract research services. Operating through three synergistic business units, Biotech, CRO, and Ventures, we combine scientific excellence with strong value creation and a firm commitment to society. Our team of 300+ employees collaborates with industry and academia to improve the quality of people’s lives.

Engitix is transforming drug discovery by harnessing the power of the extracellular matrix (ECM) to develop breakthrough therapies for fibrosis, inflammation, and solid tumors. Its proprietary, end-to-end discovery platform integrates human-derived ECM scaffolds with advanced computational and AI/ML tools, creating predictive 3D systems that mirror human biology and de-risk development. Supported by strong partnerships and validated science, Engitix is redefining how complex diseases are understood, modeled, and treated.

MedChemExpress (MCE), a premier global supplier, offers 100,000+ inhibitors & agonists targeting 20+ key pathways. We support drug discovery with our all-in-one platform, custom synthesis (ADCs, PROTACs), and specialized libraries, empowering your research with innovative tools and solutions

Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure.  Mediar’s exploratory medicines aim to disable the myofibroblast, slow fibrosis, and enable healing.  Mediar is conducting Phase 2 clinical studies to bring new potential options for patients and their caregivers.

At Optics11 Life we develop a suite of mechanobiology tools, including high-precision, high-throughput instruments for cell-to-tissue nanoindentation, and a non-destructive contractility platform that monitors 3D muscle-bundle dynamics. Together, these instruments quantify stiffness, viscoelasticity, and force generation under near-physiological conditions, giving researchers fast, actionable data for advanced disease modelling, drug screening and biomaterial quality control. Our products are used across diverse application areas, including fibrosis, oncology, cardiology, muscle diseases, and regenerative medicine.

Tribune Therapeutics is a Nordic biotech company pioneering therapies for fibrotic diseases through deep expertise in CCN biology. Its lead candidate, TRX-44, a human albumin fusion protein, targets key pro-fibrotic CCN signaling pathways to halt fibrosis progression and preserve lung function in idiopathic pulmonary fibrosis. Tribune combines cutting-edge science and strategic collaborations to deliver transformative treatments for patients worldwide.

Zealand Pharma is a biotechnology company advancing medicines for obesity and metabolic health. Combining nearly 30 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Denmark, with an office in Boston.

BiomimX is an innovative SME pioneering beating organs-on-chip technologies for advanced drug development. Leveraging its proprietary uBeat® platform, the company recreates physiological and pathological tissue functions in vitro, enabling predictive efficacy, safety, and toxicity testing. BiomimX partners with Pharma and Biotech to accelerate R&D and reduce animal experimentation.

Innoprot provides advanced cell-based assays, as well as primary, immortalised and recombinant cell lines, for drug discovery. We develop in vitro systems that enable the study of fibrosis and extracellular matrix remodelling, facilitating phenotypic and high-content analysis for compound screening and the quantification of key biomarkers

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.